CU23584A1 - Composición farmacéutica que comprende la proteína nmb1796 - Google Patents
Composición farmacéutica que comprende la proteína nmb1796Info
- Publication number
- CU23584A1 CU23584A1 CU20070151A CU20070151A CU23584A1 CU 23584 A1 CU23584 A1 CU 23584A1 CU 20070151 A CU20070151 A CU 20070151A CU 20070151 A CU20070151 A CU 20070151A CU 23584 A1 CU23584 A1 CU 23584A1
- Authority
- CU
- Cuba
- Prior art keywords
- nmb1796
- composition
- protein
- pharmaceutical composition
- composition including
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de una composición farmacéutica que comprende la proteína NMB1796. La composición de la presente invención confiere protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMB1796 se identificó como componente de las preparaciones de vesículas de membrana externa (VME) de Neisseria meningitidis, se obtuvo mediante la tecnología del ácido desoxirribonucleico (ADN) recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMB1796, la composición que la comprende posee alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. La composición de esta invención es aplicable en la medicina humana.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20070151A CU23584A1 (es) | 2007-06-27 | 2007-06-27 | Composición farmacéutica que comprende la proteína nmb1796 |
| EP08757901A EP2168595A1 (en) | 2007-06-27 | 2008-06-16 | Pharmaceutical compositions containing the protein nmb1796 |
| PCT/CU2008/000004 WO2009000217A1 (es) | 2007-06-27 | 2008-06-16 | Composición farmacéutica que comprende la proteína nmb1796 |
| US12/664,278 US20100172931A1 (en) | 2007-06-27 | 2008-06-16 | Pharmaceutical Composition Containing the NMB1796 Protein |
| ARP080102713A AR067151A1 (es) | 2007-06-27 | 2008-06-24 | Composicion farmaceutica que comprende la proteina nmb 1796 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20070151A CU23584A1 (es) | 2007-06-27 | 2007-06-27 | Composición farmacéutica que comprende la proteína nmb1796 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23584A1 true CU23584A1 (es) | 2010-10-30 |
Family
ID=39732417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20070151A CU23584A1 (es) | 2007-06-27 | 2007-06-27 | Composición farmacéutica que comprende la proteína nmb1796 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100172931A1 (es) |
| EP (1) | EP2168595A1 (es) |
| AR (1) | AR067151A1 (es) |
| CU (1) | CU23584A1 (es) |
| WO (1) | WO2009000217A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102078569B1 (ko) | 2013-12-27 | 2020-02-19 | 삼성전자 주식회사 | 무선 통신 시스템에서 빔 모드 운용을 위한 방법 장치 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004046177A2 (en) * | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
-
2007
- 2007-06-27 CU CU20070151A patent/CU23584A1/es unknown
-
2008
- 2008-06-16 WO PCT/CU2008/000004 patent/WO2009000217A1/es not_active Ceased
- 2008-06-16 US US12/664,278 patent/US20100172931A1/en not_active Abandoned
- 2008-06-16 EP EP08757901A patent/EP2168595A1/en not_active Withdrawn
- 2008-06-24 AR ARP080102713A patent/AR067151A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100172931A1 (en) | 2010-07-08 |
| WO2009000217A1 (es) | 2008-12-31 |
| EP2168595A1 (en) | 2010-03-31 |
| AR067151A1 (es) | 2009-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117757T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| PE20220400A1 (es) | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio | |
| BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
| BRPI0924460A2 (pt) | composição farmacêutica para uso em oftalmologia médica e veterinária | |
| WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
| BR112013000262A2 (pt) | controle de pragas de insetos coleópteros | |
| PT2285408T (pt) | Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais | |
| CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112015012152A2 (pt) | Proteína de fusão terapêutica direcionada que compreende uma enzima lisossomal, ácido nucleico, composição farmacêutica, método para produzir a dita proteína e usos da proteína para tratar uma doença de armazenamento lisossomal e mucopolissacaridose tipo iiib | |
| CR20120264A (es) | Compuestos | |
| BR112014001409A2 (pt) | métodos e composições para vacinação contra staphylococcus aureus | |
| BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| UA114719C2 (uk) | Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| PH12013501373B1 (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| BRPI1012078A2 (pt) | construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica | |
| BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
| NZ712713A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| AR060796A1 (es) | Composicion farmaceutica que comprende la proteina nmb0938 | |
| AR060797A1 (es) | Composicion farmaceutica que comprende la proteina nmb0606 | |
| BR112014020184A8 (pt) | Preparação farmacêutica que contém anlodipina e ra-mipril | |
| BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo |